期刊文献+

参芪扶正注射液联合多西他赛治疗中晚期非小细胞肺癌 被引量:15

Clinical Study of Shenqi Fuzheng Injection with Docetaxel on Treatment of Advanced Stage Non-small Cell Lung Cancer
原文传递
导出
摘要 目的:运用参芪扶正注射液配合化疗,观察化疗患者骨髓抑制、消化道反应、KPS评分变化。方法:将符合纳入标准的肺癌化疗病人100例,应用信封法随机分组,实验组应用PD方案化疗,同时配合使用参芪扶正注射液;对照组单纯应用PD方案化疗。观察参芪扶正注射液对化疗所致的骨髓抑制、消化道反应、KPS体力状况评分的影响。结果:实验组WBC,NEU降低程度明显小于对照组(P<0.05);实验组恶心、腹泻症状明显轻于对照组(P<0.05);实验组KPS体力状况评分降低程度极明显小于对照组(P<0.01)。结论:参芪扶正注射液能减轻化疗后血WBC、NEU的下降程度,减轻化疗引起的恶心、腹泻症状,改善化疗后患者的KPS体力状况评分。 Objective:The influence of the Shenqi Fuzheng injection to the patients who got the injection to go with the chemotherapy in hematology change,digestive response,the KPS grades along and after chemotherapy.Method:One-hundred patients were selected according to the standard of the lung cancer chemotherapy.With the quantization random controlled method,we devided the patients into two groups.The treatment group patients re-ceived the administration of Shenqi Fuzheng injection and、PD chemotherapy.The control group patients received only PD chemotherapy.We observed the influence of Shenqi Fuzheng injection on the aspects of myelosuppression,the response to chemotherapy in gastrointestinal and the KPS.Result:The reduce of the white blood cell(WBC),the neutrophilic granulocyte(NEU) in the treatment group were lower than the control group obviously(P 〈 0.05);The response to chemotherapy in gastrointestinal of the treatment group was lighter than the control group(P 〈 0.05);The reduce of KPS were lower than the control group obviously(P 〈 0.01).Conclusion:Shenqi Fuzheng in-jection can reduce the decrease of WBC,NEU after the chemotherapy,Shenqi Fuzheng injection can reduce the chemotherapy-induced nausea and diarrhea,Shenqi Fuzheng injection can improve the patient ’s KPS physical strength condition
出处 《中国实验方剂学杂志》 CAS 北大核心 2011年第5期231-232,共2页 Chinese Journal of Experimental Traditional Medical Formulae
关键词 肺癌 参芪扶正注射液 化疗 lung cancer Shenqi Fuzheng injection chemotherapy
  • 相关文献

参考文献6

  • 1Shepherd F,Dancey J,RamLau R,et al.A prospective randomized trail of docetaxel (Taxotere) versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-basedchemotherapy[J].J Clin Oncol,2000,18:2095. 被引量:1
  • 2Fossella F V,De Vore R,Kerr R N,et al.Randonmized phase Ⅲ trail of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens[J].J Clin Oncol,2000,18:2354. 被引量:1
  • 3Fukuoka M,Yano S,Giaccone G,et al.Final results from a phase Ⅱ trial of ZD1839 (Iressa) for patients with advanced norrsmall cell lung cancer (IDEAL 1)[J].Proc Am Soc Clin Oncol,2002,21:298a. 被引量:1
  • 4Kris R B,Natale R S,Herbst T J,et al.A phase Ⅱ trial of ZD1839(Iressa) in advanced non-s mall cell lung cancer (NSCLC) patients who had failed platinum-and docetaxelbased regimens(IDEAL 2)[J].Proc Am Soc Clin Oncol,2002,21:292a. 被引量:1
  • 5孙燕主编..内科肿瘤学[M].北京:人民卫生出版社,2001:1016.
  • 6梅宏,陈志昌.参芪扶正注射液对肺癌患者手术后免疫功能的调节作用[J].四川大学学报(医学版),2005,36(3):449-450. 被引量:25

二级参考文献5

共引文献24

同被引文献167

引证文献15

二级引证文献184

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部